Triple

T17377846
Position Surface form Disambiguated ID Type / Status
Subject Cambridge Antibody Technology E422486 entity
Predicate collaboratedWith P435 FINISHED
Object Daiichi Sankyo NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Daiichi Sankyo | Statement: [Cambridge Antibody Technology, collaboratedWith, Daiichi Sankyo]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Daiichi Sankyo
Context triple: [Cambridge Antibody Technology, collaboratedWith, Daiichi Sankyo]
  • A. Daiichi Sankyo chosen
    Daiichi Sankyo is a major Japanese global pharmaceutical company known for developing innovative medicines, particularly in cardiovascular disease and oncology.
  • B. Eisai
    Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
  • C. Eisai
    Eisai was a Japanese Buddhist monk of the Kamakura period best known for introducing Rinzai Zen and promoting tea culture in Japan.
  • D. Chugai Pharmaceutical
    Chugai Pharmaceutical is a major Japanese research-based pharmaceutical company known for its innovative biopharmaceuticals and strategic alliance with Roche.
  • E. Takeda Pharmaceutical Company
    Takeda Pharmaceutical Company is a leading global biopharmaceutical firm headquartered in Japan, focused on developing innovative medicines in areas such as oncology, gastroenterology, neuroscience, and rare diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d889d6535c81908be333c01deaec4e completed April 10, 2026, 5:25 a.m.
NER Named-entity recognition batch_69e43a6ea56c8190b56d966ccf2c91f7 completed April 19, 2026, 2:14 a.m.
Created at: April 10, 2026, 5:45 a.m.